| Code | CSB-RA011664MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Clazakizumab, targeting interleukin-6 (IL-6), a pleiotropic pro-inflammatory cytokine that plays a central role in immune regulation and inflammatory responses. IL-6 is secreted by various cell types including T cells, macrophages, and fibroblasts, and mediates its effects through both classical and trans-signaling pathways involving the IL-6 receptor and gp130. Dysregulated IL-6 signaling is implicated in numerous pathological conditions including rheumatoid arthritis, cytokine release syndrome, antibody-mediated transplant rejection, and various autoimmune disorders. Elevated IL-6 levels are also associated with chronic inflammatory states and certain malignancies.
Clazakizumab is a high-affinity humanized IgG1 monoclonal antibody that directly binds and neutralizes IL-6, preventing its interaction with membrane-bound and soluble IL-6 receptors. This biosimilar provides researchers with a valuable tool for investigating IL-6-mediated inflammatory pathways, studying cytokine signaling mechanisms, and evaluating therapeutic strategies in preclinical models of inflammation and immune-mediated diseases.
There are currently no reviews for this product.